Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.

Saved in:
Bibliographic Details
Title: Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
Authors: Garon EB; Department of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California. Electronic address: egaron@mednet.ucla.edu., Spira AI; Co-Director, Virginia Cancer Specialists Research Institute and NEXT Oncology, Fairfax, Virginia., Goldberg SB; Department of Internal Medicine, Yale Cancer Center, New Haven, Connecticut., Chaft JE; Department of Medicine, Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center, New York, New York., Papadimitrakopoulou V; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Cascone T; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Antonia SJ; H. Lee Moffitt Cancer Center, Tampa, Florida., Brahmer JR; Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland., Camidge DR; Department of Medicine-Medical Oncology, University of Colorado Cancer Center, Denver, Colorado., Powderly JD; Carolina BioOncology Institute, Huntersville, North Carolina., Wozniak AJ; Department of Medicine, University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania., Felip E; Deparmtent of Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Wu S; Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland., Ascierto ML; Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland., Elgeioushi N; Oncology Research and Development, AstraZeneca, Gaithersburg, Maryland., Awad MM; Dana-Farber Cancer Institute, Boston, Massachusetts.
Source: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2023 Aug; Vol. 18 (8), pp. 1094-1102. Date of Electronic Publication: 2023 May 04.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1556-1380
DOI:10.1016/j.jtho.2023.04.020